Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed ...

. About Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Pluvicto is an intravenous radioligand therapy (RLT) combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive ...

Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of ...

Disclaimer: This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be ...

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.

What would you say if I told you that 1 + 1 = >2? It may sound extraordinary, but it is an accurate reflection of the work I am currently doing in the field of drug discovery with my team of AI ...

1. Le valute costanti (vc), i risultati dell’attività core e il flusso di cassa libero sono dati non IFRS. La spiegazione dei dati non IFRS è riportata a pagina 34 della Relazione finanziaria ...